Literature DB >> 32775770

Radiation Therapy Care During a Major Outbreak of COVID-19 in Wuhan.

Shen Wu1, Dandan Zheng2, Yongsheng Liu1, Desheng Hu1, Wei Wei1, Guang Han1.   

Abstract

PURPOSE: The epidemic of coronavirus disease 2019 (COVID-19) challenges the prevention and protection of the cancer patients and the staff in the department of radiation oncology.
METHODS: At the Hubei Cancer Hospital, we organized an emergency infection control team to lead special efforts to combat COVID-19 during this challenging time.
RESULTS: Radiation therapy treatments were resumed on January 30th and have never stopped again at the hospital regardless of the circumstances of the ongoing outbreak. Between January 30th and the time of the writing, we have treated over 100 radiation therapy patients, with no incidence of on-site COVID-19 transmission between patients and health care workers in the duration.
CONCLUSIONS: Our experience will help guide the practice in other regions that are or might be facing outbreaks of this disease.
© 2020 The Authors.

Entities:  

Year:  2020        PMID: 32775770      PMCID: PMC7270882          DOI: 10.1016/j.adro.2020.03.004

Source DB:  PubMed          Journal:  Adv Radiat Oncol        ISSN: 2452-1094


In December 2019, cases of an unexplained new type of pneumonia started to appear in Wuhan, China. This was soon confirmed to be caused by a novel coronavirus (2019n-CoV). The acute respiratory infectious disease caused by 2019-nCoV was later termed coronavirus disease 2019 (COVID-19). During the first month of the outbreak, there were 16,500 confirmed cases, 360 fatalities, and over 20,000 suspected cases in China, with the vast majority of cases in Wuhan. With medical support from other regions of China and the world and after nearly 2 months of lockdown, the COVID-19 epidemic in Wuhan seems to be under control, with new confirmed cases currently recorded at a daily tally in single digits. However, the epidemic has since spread internationally and is breaking out in many other countries across different continents. By March 11, 2020, the rapid spread of the virus had caused more than 118,000 cases and 4291 deaths in 114 countries. The World Health Organization declared that the epidemic of COVID-19 had become a “global pandemic.” Radiation therapy is a mainstay treatment for patients with cancer and usually involves treatment delivered over days to weeks. Previous studies have reported that a protracted radiation therapy course or treatment interruption contributes to inferior local control and overall survival in patients with cancer., It is a unique challenge to provide radiation oncology care to patients with cancer during such a major outbreak without radiation therapy interruption or protracted radiation therapy time. Infection prevention and control are critical both for this susceptible patient population with often compromised immune systems and for health care workers. This article briefly reviews the radiation therapy management in Wuhan since January 2020, with the hope that the experience learned and the lessons learned will help guide practice in other regions that are or might be facing outbreaks of this disease. In early January, because the hospitals in Wuhan were yet unclear about the disease outbreak, radiation therapy deliveries were conducted as normal at various cancer centers in Wuhan. Neither mask-wearing nor hand hygiene was enforced for patients or medical staff, and there was no regular disinfection of the linear accelerators. Around January 20, person-to-person transmission between patients and staff was reported at a tertiary referral (Grade A) hospital affiliated with a prestigious university in Wuhan. As a result, several radiation oncologists, 2 radiation therapists, and an unknown number of patients were infected with 2019n-CoV. January 23, 2020 was Chinese New Year. Therefore, all radiation oncology centers in Wuhan had a planned closure with no treatment delivery until January 27. However, COVID-19 rapidly spread in Wuhan during the break. With no COVID-19 prevention guidelines prepared, most centers that reopened on January 27 stopped treating again after having resumed radiation therapy delivery for 1 or a few days because of more infections of patients and/or staff. The only hospital specializing in oncology in Wuhan, the Hubei Cancer Hospital, did not resume treatment on January 27. Instead, efforts were made to develop a COVID-19 prevention workflow and standards, to disinfect treatment vaults, and to design and develop appropriate isolation zoning. Thereafter, radiation therapy treatments were resumed on January 30 and have stopped again at the hospital regardless of the circumstances of the ongoing outbreak. The COVID-19–specific practice guidelines we put in place are as follows: Patient screening: All patients receiving radiation therapy at our hospital must be screened for COVID-19. Only patients for whom COVID-19 has been ruled out can receive treatment. Health education for patients: We developed a radiation therapy informed consent form. Before receiving radiation therapy, the patient is informed of the risk of cross-contamination during treatments and signs the informed consent. The patient is also informed of the zoning design of the radiation therapy center, the radiation therapy workflow during the outbreak, and the necessary personal protection for the patient. Health care worker screening: According to the COVID-19 diagnosis guidelines, staff returning to work must be screened for the disease. Only those cleared by the screening can return to their posts. Staff training: Before returning to their posts, staff receive training on COVID-19 prevention and protection. Staff learn the protection level of their corresponding role and the appropriate personal protection equipment for the role (a radiation therapist wearing personal protection equipment during treatment delivery is shown in Fig 1), as well as the dons and doffs.
Figure 1

Example picture showing a radiation therapist in personal protection equipment (PPE) (gowns, N-95 masks, gloves, and protective eyewear) delivering radiation therapy treatment at the console.

Example picture showing a radiation therapist in personal protection equipment (PPE) (gowns, N-95 masks, gloves, and protective eyewear) delivering radiation therapy treatment at the console. Zoning: The radiation therapy center is zoned into different contamination levels (Clean Zone, Semi-soiled/Semi-contaminated Zone, and Soiled/Contaminated Zone) and is periodically disinfected following corresponding frequencies and protocols. The protection level needed for each zone level is clearly defined. Special considerations for immobilization devices: Special modifications are put in place for certain immobilization devices during the outbreak. For example, surgical masks are used under the thermoplastic mask for cranial or head and neck patients (Fig 2); single-use clear wrap is applied to immobilization devices.
Figure 2

Example picture showing 2 radiation therapists in personal protection equipment (PPE) setting up a patient with glioblastoma with a modified thermoplastic mask immobilization device with a surgical mask underneath.

Example picture showing 2 radiation therapists in personal protection equipment (PPE) setting up a patient with glioblastoma with a modified thermoplastic mask immobilization device with a surgical mask underneath. A special radiation therapy treatment workflow is designed to avoid patient–patient contact and minimize patient–staff interaction time. Between January 30 and the time of this writing, we have treated over 100 radiation therapy patients, with no incidence of on-site COVID-19 transmission between patients and health care workers in this duration. This suggests that the protection practice guidelines we put in place are effective and may be helpful for other radiation therapy centers.
  4 in total

1.  Novel coronavirus: how things are in Wuhan.

Authors:  S Khan; G Nabi; G Han; R Siddique; S Lian; H Shi; N Bashir; A Ali; M Adnan Shereen
Journal:  Clin Microbiol Infect       Date:  2020-02-11       Impact factor: 8.067

2.  Effect of Prolonged Radiotherapy Treatment Time on Survival Outcomes after Intensity-Modulated Radiation Therapy in Nasopharyngeal Carcinoma.

Authors:  Pei-Jing Li; Ting Jin; Dong-Hua Luo; Ting Shen; Dong-Mei Mai; Wei-Han Hu; Hao-Yuan Mo
Journal:  PLoS One       Date:  2015-10-27       Impact factor: 3.240

3.  The detrimental effects of radiotherapy interruption on local control after concurrent chemoradiotherapy for advanced T-stage nasopharyngeal carcinoma: an observational, prospective analysis.

Authors:  Ji-Jin Yao; Ya-Nan Jin; Si-Yang Wang; Fan Zhang; Guan-Qun Zhou; Wang-Jian Zhang; Jun Ma; Zhen-Yu Qi; Ying Sun
Journal:  BMC Cancer       Date:  2018-07-16       Impact factor: 4.430

4.  The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health - The latest 2019 novel coronavirus outbreak in Wuhan, China.

Authors:  David S Hui; Esam I Azhar; Tariq A Madani; Francine Ntoumi; Richard Kock; Osman Dar; Giuseppe Ippolito; Timothy D Mchugh; Ziad A Memish; Christian Drosten; Alimuddin Zumla; Eskild Petersen
Journal:  Int J Infect Dis       Date:  2020-01-14       Impact factor: 3.623

  4 in total
  11 in total

1.  The impact of COVID-19 on a high-volume incident learning system: A retrospective analysis.

Authors:  Dustin J Jacqmin; Jennie S M Crosby
Journal:  J Appl Clin Med Phys       Date:  2022-05-26       Impact factor: 2.243

Review 2.  Novel coronavirus mitigation measures implemented by radiotherapy centres in low and middle-income countries: a systematic review.

Authors:  Andrew Donkor; Vivian Della Atuwo-Ampoh; Craig Opie; Frederick Yakanu; Dorothy Lombe; Jamal Khader
Journal:  Rep Pract Oncol Radiother       Date:  2021-04-14

3.  Impact of the COVID-19 Pandemic on Radiotherapy Supply.

Authors:  Francesco Tramacere; Artor Niccoli Asabella; Maurizio Portaluri; Corinna Altini; Cristina Ferrari; Lilia Bardoscia; Angela Sardaro
Journal:  Radiol Res Pract       Date:  2021-05-05

4.  Nationwide survey of COVID-19 prevention measures in Japanese radiotherapy departments via online questionnaire for radiation oncologists.

Authors:  Keisuke Tamari; Yasushi Nagata; Shingo Nishiki; Satoaki Nakamura; Kazuhiko Ogawa; Takashi Uno
Journal:  Radiother Oncol       Date:  2020-05-29       Impact factor: 6.280

5.  Practical indications for management of patients candidate to Interventional and Intraoperative Radiotherapy (Brachytherapy, IORT) during COVID-19 pandemic - A document endorsed by AIRO (Italian Association of Radiotherapy and Clinical Oncology) Interventional Radiotherapy Working Group.

Authors:  Andrea Vavassori; Luca Tagliaferri; Lisa Vicenzi; Andrea D'Aviero; Antonella Ciabattoni; Sergio Gribaudo; Loredana Lapadula; Gian Carlo Mattiucci; Lorenzo Vinante; Vitaliana De Sanctis; Cristiana Vidali; Rita Murri; Maria Antonietta Gambacorta; Marcello Mignogna; Barbara A Jereczek-Fossa; Vittorio Donato
Journal:  Radiother Oncol       Date:  2020-05-08       Impact factor: 6.280

6.  Impact of the COVID-19 Pandemic on Patients and Staff in Radiation Oncology Departments in Belgium: A National Survey.

Authors:  Aude Vaandering; Selma Ben Mustapha; Maarten Lambrecht; Dirk Van Gestel; Liv Veldmeman
Journal:  Front Oncol       Date:  2021-03-19       Impact factor: 6.244

7.  COVID-19 outbreak and cancer radiotherapy disruption in Italy: Survey endorsed by the Italian Association of Radiotherapy and Clinical Oncology (AIRO).

Authors:  Barbara Alicja Jereczek-Fossa; Matteo Pepa; Giulia Marvaso; Alessio Bruni; Michela Buglione di Monale E Bastia; Gianpiero Catalano; Andrea Riccardo Filippi; Pierfrancesco Franco; Maria Antonietta Gambacorta; Domenico Genovesi; Giuseppe Iatì; Alessandro Magli; Luigi Marafioti; Icro Meattini; Anna Merlotti; Marcello Mignogna; Daniela Musio; Roberto Pacelli; Stefano Pergolizzi; Vincenzo Tombolini; Marco Trovò; Umberto Ricardi; Stefano Maria Magrini; Renzo Corvò; Vittorio Donato
Journal:  Radiother Oncol       Date:  2020-05-12       Impact factor: 6.280

8.  Risk factors and action thresholds for the novel coronavirus pandemic. Insights from the Italian Society of Nephrology COVID-19 Survey.

Authors:  Maurizio Nordio; Gianpaolo Reboldi; Anteo Di Napoli; Giuseppe Quintaliani; Federico Alberici; Maurizio Postorino; Filippo Aucella; Piergiorgio Messa; Giuliano Brunori
Journal:  J Nephrol       Date:  2021-01-02       Impact factor: 3.902

9.  Measures of infection prevention and incidence of SARS-CoV-2 infections in cancer patients undergoing radiotherapy in Germany, Austria and Switzerland.

Authors:  Christiane Matuschek; Johannes C Fischer; Stephanie E Combs; Rainer Fietkau; Stefanie Corradini; Kurt Zänker; Edwin Bölke; Freddy-Joel Djiepmo-Njanang; Balint Tamaskovics; Joachim E Fischer; Martin Stuschke; Christoph Pöttgen; Robert Förster; Daniel R Zwahlen; Alexandros Papachristofilou; Ute Ganswindt; Rainer Pelka; E Marion Schneider; Torsten Feldt; Björn Erik Ole Jensen; Dieter Häussinger; Wolfram Trudo Knoefel; Detlef Kindgen-Milles; Alessia Pedoto; Olaf Grebe; Martijn van Griensven; Wilfried Budach; Jan Haussmann
Journal:  Strahlenther Onkol       Date:  2020-09-10       Impact factor: 3.621

10.  Delayed Intravitreal Anti-VEGF Therapy for Patients During the COVID-19 Lockdown: An Ethical Endeavor.

Authors:  Mutasem Elfalah; Saif Aldeen AlRyalat; Mario Damiano Toro; Robert Rejdak; Sandrine Zweifel; Rashed Nazzal; Mohammed Abu-Ameerh; Osama Ababneh; Almutez Gharaibeh; Zuhair Sharif; Jehad Meqbil; Mo'ath AlShawabkeh; Amal Alwreikat; Muawyah Al Bdour; Maysa Al-Hussaini; Yacoub A Yousef
Journal:  Clin Ophthalmol       Date:  2021-02-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.